Cologne, Germany
September 19, 2001

A recombinant single chain antibody produced in potato tubers by MPB Cologne GmbH, the Molecular Farming company based in Cologne, Germany, has proven to be functionally equivalent to its bacteria-produced counterpart in stimulating outgrowth of neurites from cultured neurons.

In cooperation with Prof. Melitta Schachner, University of Hamburg, Germany, the experimental assessment in her laboratory revealed no difference between the antibody derived from established bacterial production and that produced in potato tubers. She commented: "We are highly delighted to have access to MPB´s cutting edge Industrial Tuber™ technology for antibody production. Our experiments have demonstrated that this novel technology provides a product which is functionally equivalent in cell cultures."

The antibody, directed against the neural recognition molecules L1 from mouse, was developed in the laboratory of Melitta Schachner. It stimulates neurite outgrowth of cultured mouse neurons. Antibodies against the human L1 protein may have potential as biotherapeutic agent for the treatment of neurodegenerative diseases such as Alzheimer, Parkinson and multiple sclerosis.

Dr. Klaus Düring, President & CEO of MPB Cologne, said: "MPB´s technology contributes to biotherapeutics development by making proteins available in larger amounts and at lower cost than presently possible. The Industrial Tuber™ technology may give the public access to new and effective medicines at affordable prices. Our cooperation with Melitta Schachner has confirmed the high quality of the potato-derived product."

MPB Cologne develops and produces novel proteins as materials and active agents by Molecular Farming in genetically optimized potato tubers for industry customers and partners. The Industrial Tuber™ is used as a plant bioreactor for economical large-scale production with highest biosafety and quality standards.

Company news release
mpb10